Jacobio Pharma

Jacobio concentrates on historically undruggable targets, building its discovery capability around an induced-allosteric drug discovery platform that maps cryptic allosteric binding sites and converts them into selective small-molecule inhibitor programs.

The company pairs the platform with a leadership team that previously built Betta Pharmaceuticals and commercialized China's first targeted anti-cancer drug, and it has repeatedly struck partnerships with global pharmaceutical companies including AbbVie, AstraZeneca, Merck, and Allist.

Jacobio's addressable markets center on KRAS-driven cancers, where glecirasib competes in a therapeutic class defined by the first-generation KRAS G12C inhibitors, and on broader RAS pathway mutations that still lack approved targeted options.

Its pan-KRAS program partnered with AstraZeneca and its SHP2 combination strategy position it in the next wave of RAS-targeted therapy, while the 2025 China approval of glecirasib and the company's first profitable half-year in 2026 mark its transition toward commercial operations.

Jacobio's pipeline is organized around six oncogenic signaling pathways: RAS, P53, RB, MYC, immune checkpoints, and tumor metabolism. Its most advanced asset is glecirasib, an irreversible KRAS G12C inhibitor approved in China for previously treated KRAS G12C-mutated non-small cell lung cancer and included in the National Reimbursement Drug List.

Other clinical programs include the SHP2 inhibitor sitneprotafib in registrational combination trials, the pan-KRAS inhibitor JAB-23E73 licensed to AstraZeneca for markets outside mainland China, and earlier-stage programs spanning BET, Aurora A, P53 Y220C, and CD73 targets.